Needham & Company LLC reiterated their buy rating on shares of Geron (NASDAQ:GERN - Free Report) in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has a $5.00 target price on the biopharmaceutical company's stock.
GERN has been the subject of several other reports. Wedbush reiterated an outperform rating and issued a $6.00 price target on shares of Geron in a report on Wednesday. The Goldman Sachs Group boosted their price target on Geron from $4.00 to $5.00 and gave the company a buy rating in a report on Friday, March 15th.
Read Our Latest Report on GERN
Geron Price Performance
GERN stock traded up $0.33 on Thursday, reaching $3.77. The company had a trading volume of 18,551,011 shares, compared to its average volume of 11,229,023. Geron has a 1 year low of $1.64 and a 1 year high of $3.79. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.16 and a current ratio of 3.16. The company's fifty day moving average is $2.53 and its 200 day moving average is $2.17. The company has a market cap of $2.06 billion, a P/E ratio of -11.42 and a beta of 0.62.
Geron (NASDAQ:GERN - Get Free Report) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Geron had a negative return on equity of 63.33% and a negative net margin of 77,691.14%. Geron's revenue was down 77.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.10) EPS. On average, research analysts forecast that Geron will post -0.34 earnings per share for the current year.
Institutional Trading of Geron
A number of institutional investors and hedge funds have recently made changes to their positions in GERN. Pathstone Family Office LLC acquired a new stake in shares of Geron during the 3rd quarter worth $26,000. Cerity Partners LLC acquired a new stake in Geron in the 4th quarter valued at $26,000. Creative Planning acquired a new stake in Geron in the 3rd quarter valued at $26,000. CIBC Asset Management Inc acquired a new stake in Geron in the 4th quarter valued at $27,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Geron by 101.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 6,757 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.
Geron Company Profile
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Stories
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
